Over-Impacted, Under-Represented: Addressing Health Disparities in Multiple Sclerosis
The prevalence of MS in racial and ethnic minority groups appears to be growing and its prognosis among these groups is often worse. With its historical management strategies formulated almost exclusively around patients of Caucasian descent, MS has a pressing need for improved approaches in patients of minority backgrounds. However, minimal guidance is publicly available on how to best meet the needs of diverse patient populations. Some of the greatest barriers to patient care among minority groups are their perceptions and experiences with healthcare providers. The organizers hope to address this gap by documenting the perspectives of racial and ethnic minority patients related to their MS care. These perspectives will then be embedded into expert discussion alongside supporting evidence of and resources to help providers address the issues raised. This unique CME initiative will enable learners to develop more culturally conscious clinical and communication-based skills to better assess and address the needs of minority patients with MS.
The target audience for this initiative includes MS specialists, general neurologists, nurse practitioners, physician assistants and other healthcare professionals involved in the diagnosis and long-term management of patients with MS.
Upon completion of this activity, participants should be better able to:
- Identify key variations in clinical presentation between different racial/ethnic populations with MS, and use these to apply individualized treatment strategies to achieve improved outcomes for these patients.
- Discuss sociocultural views that may discourage racial and ethnic minority groups from seeking and/or complying with medical care, and apply strategies to form a comfortable and supportive management approach for patients of different backgrounds.
- Identify both interpersonal and publicly available approaches to the support of clinical trial engagement among racial and ethnic minority patients with MS in order to better inform and encourage patient participation.
Mitzi Williams, MD, FAAN
Neurologist and Multiple Sclerosis Specialist
Founder and Medical Director, Joi Life Wellness Group
Annette Okai, MD
Director, Neuroimmunology and Multiple Sclerosis Research
North Texas Institute of Neurology and Headache
Clinical Associate Professor of Neurology
Texas Tech University Health Science Center
Stephen Krieger, MD, FAAN
Associate Professor of Neurology
Icahn School of Medicine at Mount Sinai
Corinne Goldsmith Dickinson Center for MS
New York, NY
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and Efficient LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.
Purdue designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflict of Interest
All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity.
Planners' and Managers' Disclosure
All additional planning committee members, staff and reviewers of Efficient LLC and Purdue University College of Pharmacy have no relationships to disclose.
Dr Okai reported the following financial relationships:
- Grants/Research Support: Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme
- Principal Investigator for a Drug Study: Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi Genzyme
- Consultant: Biogran, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi Genzyme
Dr Krieger reported the following financial relationships:
- Grants/Research Support: Biogen, BMS Novartis
- Principal Investigator for a Drug Study: Sanofi
- Consultant: Biogen, EMD Serono, Genentech, Genzyme/Sanofi, Novartis, Octave, TG Therapeutics
- Honorarium Recipient (Non-CE Related): Non-promotional speaking with Biogen, EMD Serono, Genentech
Dr Williams reported the following financial relationships:
- Grants/Research Support: EMD Serono, Genentech, Novartis
- Consultant: Abbvie, Alexion, Biogen Idec, Bristol Myers Squibb, EMD Serono, Genentech, Jansen, Novartis, Sanofi Genzyme, TG Therapeutics
- Speakers Bureau: Abbvie, Biogen Idec, Bristol Myers Squibb, EMD Serono, Genentech, Jansen, Novartis, Sanofi Genzyme
- Advisory Board Membership: Abbvie, Alexion, Biogen Idec, Bristol Myers Squibb, EMD Serono, Genentech, Jansen, Novartis, Sanofi Genzyme, TG Therapeutics
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC and EMD Serono.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance